Compare Cipla with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PFIZER - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PFIZER CIPLA/
PFIZER
 
P/E (TTM) x 23.3 32.6 71.4% View Chart
P/BV x 2.4 5.5 43.5% View Chart
Dividend Yield % 0.7 0.6 108.5%  

Financials

 CIPLA   PFIZER
EQUITY SHARE DATA
    CIPLA
Mar-19
PFIZER
Mar-18
CIPLA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6782,365 28.7%   
Low Rs4841,625 29.8%   
Sales per share (Unadj.) Rs198.2430.3 46.1%  
Earnings per share (Unadj.) Rs18.578.7 23.5%  
Cash flow per share (Unadj.) Rs35.093.2 37.5%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %0.51.0 51.5%  
Book value per share (Unadj.) Rs186.3586.5 31.8%  
Shares outstanding (eoy) m805.7045.75 1,761.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.94.6 63.2%   
Avg P/E ratio x31.425.3 123.7%  
P/CF ratio (eoy) x16.621.4 77.6%  
Price / Book Value ratio x3.13.4 91.7%  
Dividend payout %16.225.4 63.7%   
Avg Mkt Cap Rs m468,03191,271 512.8%   
No. of employees `00022.62.6 861.0%   
Total wages/salary Rs m28,5653,143 908.9%   
Avg. sales/employee Rs Th7,053.17,484.8 94.2%   
Avg. wages/employee Rs Th1,261.51,195.0 105.6%   
Avg. net profit/employee Rs Th659.11,369.1 48.1%   
INCOME DATA
Net Sales Rs m159,71019,685 811.3%  
Other income Rs m4,7661,143 417.0%   
Total revenues Rs m164,47520,828 789.7%   
Gross profit Rs m30,9735,003 619.1%  
Depreciation Rs m13,263663 2,002.0%   
Interest Rs m1,6844 40,102.4%   
Profit before tax Rs m20,7915,479 379.5%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6951,878 303.2%   
Profit after tax Rs m14,9243,601 414.5%  
Gross profit margin %19.425.4 76.3%  
Effective tax rate %27.434.3 79.9%   
Net profit margin %9.318.3 51.1%  
BALANCE SHEET DATA
Current assets Rs m124,26624,167 514.2%   
Current liabilities Rs m37,7159,544 395.2%   
Net working cap to sales %54.274.3 73.0%  
Current ratio x3.32.5 130.1%  
Inventory Days Days9155 164.5%  
Debtors Days Days9529 330.5%  
Net fixed assets Rs m105,1909,514 1,105.7%   
Share capital Rs m1,611458 352.2%   
"Free" reserves Rs m148,51126,375 563.1%   
Net worth Rs m150,12326,832 559.5%   
Long term debt Rs m38,30125 153,202.8%   
Total assets Rs m239,63336,900 649.4%  
Interest coverage x13.31,305.5 1.0%   
Debt to equity ratio x0.30 27,382.5%  
Sales to assets ratio x0.70.5 124.9%   
Return on assets %6.99.8 70.9%  
Return on equity %9.913.4 74.1%  
Return on capital %11.820.4 58.0%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41022 256,292.4%   
Fx outflow Rs m19,0411,489 1,279.1%   
Net fx Rs m38,368-1,466 -2,616.7%   
CASH FLOW
From Operations Rs m16,9113,318 509.7%  
From Investments Rs m-16,687-2,383 700.2%  
From Financial Activity Rs m-3,487-1,104 316.0%  
Net Cashflow Rs m-3,451-169 2,048.1%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 63.9 32.6%  
Indian inst/Mut Fund % 12.2 7.5 162.7%  
FIIs % 23.7 4.9 483.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 23.7 110.5%  
Shareholders   161,166 85,207 189.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   VENUS REMEDIES  ORCHID PHARMA LTD  GSK PHARMA  J.B.CHEMICALS  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; HDFC and TCS Top Gainers(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.1% while the Hang Seng is up 0.9%

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 17, 2019 10:33 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS